The U.S. Centers for Disease Control and Prevention (CDC) today published an updated Level 2 advisory that identified about thirty countries where poliovirus is an active health risk.
Reissued on June 15, 2023, the CDC's Global Polio alert says before traveling to any destination listed, the CDC recommends that adults who previously completed the full, routine polio vaccine series receive a single, lifetime booster dose of polio vaccine.

The U.K. Health Security Agency (UKHSA) today announced it had modified its mpox outbreak vaccination program, which was scheduled to end in July 2023.
The UKHSA confirmed on June 16, 2023, that mpox vaccinations will remain available in London after 11 new cases were diagnosed within the past few weeks.
Most of these mpox cases were in unvaccinated individuals, but three were in those who had only received one dose of the JYNNEOS® (MVA-BN) vaccine.

The World Health Organization (WHO) recently published Influenza Update N° 447, which reported influenza detections decreased further in the northern hemisphere. In contrast, some countries in the southern hemisphere reported an increase in recent weeks.
In the temperate zones of the northern hemisphere, influenza activity continued to decrease and was reported at low levels or below the seasonal threshold in most reporting countries.
As of June 12, 2023, the WHO confirmed in Oceania, influenza activity increased slightly, following trends similar to previous seasons.

When the Florida Department of Health (DOH) and the Centers for Disease Control and Prevention (CDC) confirmed a sporadic local case of Plasmodium vivax malaria in Sarasota and Manatee Counties in May 2023, most Floridians were surprised as most malaria cases diagnosed in the United States are imported.
The DOH and CDC stated on June 2, 2023, locally acquired mosquito-transmitted malaria cases could occur, as Anopheles mosquitoes are found throughout the U.S.

The Florida Department of Health (DOH) in Sarasota and Manatee Counties in Florida recently responded to one confirmed malaria case among an individual who spent extensive time outdoors.
The malaria patient was promptly treated at a hospital and has recovered.
This case has been identified as the P. vivax malaria species, which is not as fatal as other parasite species.
Only infected Anopheles mosquitos can transmit malaria to humans. This case confirms that locally acquired mosquito-transmitted malaria cases can occur in the U.S.

The U.S. Food and Drug Administration (FDA) announced updated recommendations for good clinical practices (GCPs) to modernize the design and conduct of clinical trials, making them more agile without compromising data integrity or participant protections.
Proposed in June 2023, the draft guidance is adopted from the International Council for Harmonisation's (ICH) recently updated E6(R3) draft guideline developed to enable the incorporation of rapidly evolving technological and methodological innovations into the clinical trial enterprise. 

A new analysis of 21 surveys published by Heath Affairs indicates changing attitudes about several topics, including trusting vaccine information.
Published on June 6, 2023, these opinion polls were conducted shortly before or during the recent pandemic (2015–23) that met quality standards set by the American Association of Public Opinion Research.

A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).

A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).

A meeting of the U.S. FDA's Antimicrobial Drugs Advisory Committee is scheduled for June 8, 2023, to discuss the biologics license application (BLA) for nirsevimab (Beyfortus®), a long-acting respiratory syncytial virus (RSV) F protein inhibitor, single dose monoclonal antibody (mAbs).